The Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Disc Medicine, Inc. following allegations that the company may have issued materially misleading business information. The investigation stems from a February 13, 2026 announcement that the U.S. Food and Drug Administration issued a Complete Response Letter regarding Disc Medicine's bitopertin program, stating it could not approve the new drug application due to uncertainties requiring additional evidence. On that news, Disc Medicine's stock price fell 22%. The Rosen Law Firm is preparing a class action seeking recovery of investor losses and encourages affected shareholders to contact the firm.
Disc Medicine Inc.FDA issued Complete Response Letter rejecting bitopertin, causing 22% stock drop and securities investigation.